CV 9104

Drug Profile

CV 9104

Alternative Names: CV-9104; RNActive®-derived prostate cancer vaccine

Latest Information Update: 14 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CureVac
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 08 Sep 2017 Safety and efficacy data from a phase I/II trial presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 16 Feb 2017 CureVAc terminates a phase IIb clinical trial in Prostate cancer (Hormone refractory, Metastatic disease) as stated that follow up period after primary analysis was prematurely stopped because more mature data will not impact the study outcome in Poland, France, United Kingdom, Switzerland, Sweden, Spain, Germany and Czech Republic (Intradermal) (NCT01817738)
  • 29 Apr 2016 CureVac terminates a phase II clinical trial in Prostate cancer (first-line therapy, in intermediate or high-risk disease) in Germany (Intradermal) (EudraCT2013-004489-32)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top